Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis-Reference-Cited by-同舟云学术

Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

Published:2023-09-08 Issue:36 Volume:9 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Liang Barry J.¹²^ORCID,Pang Sumiao¹^ORCID,Perttila Robert³^ORCID,Ma Chen-Hua¹,Srivastava Payal¹^ORCID,Gaitan Brandon¹,Sorrin Aaron J.¹,Fadul Nada¹^ORCID,Rahman Idrisa¹²,Ylniemi Zoe³,Roque Dana M.⁴⁵^ORCID,Hasan Tayyaba⁶^ORCID,Uusimaa Petteri³^ORCID,Huang Huang-Chiao¹⁴^ORCID

Affiliation:

1. Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.

2. Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

3. Modulight Corporation, Tampere, Finland.

4. Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

5. Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

6. Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Abstract

Fluorescence-guided intervention can bolster standard therapies by detecting and treating microscopic tumors before lethal recurrence. Tremendous progress in photoimmunotherapy and nanotechnology has been made to treat metastasis. However, many are lost in translation due to heterogeneous treatment effects. Here, we integrate three technological advances in targeted photo-activable multi-agent liposome (TPMAL), fluorescence-guided intervention, and laser endoscopy (ML7710) to improve photoimmunotherapy. TPMAL consists of a nanoliposome chemotherapy labeled with fluorophores for tracking and photosensitizer immunoconjugates for photoimmunotherapy. ML7710 is connected to Modulight Cloud to capture and analyze multispectral emission from TPMAL for fluorescence-guided drug delivery (FGDD) and fluorescence-guided light dosimetry (FGLD) in peritoneal carcinomatosis mouse models. FGDD revealed that TPMAL enhances drug delivery to metastases by 14-fold. ML7710 captured interpatient variability in TPMAL uptake and prompted FGLD in >50% of animals. By combining TPMAL, ML7710, and fluorescence-guided intervention, variation in treatment response was substantially reduced and tumor control improved without side effects.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/sciadv.adi3441

Reference46 articles.

1. Cancer statistics, 2023

2. Ovarian cancer statistics, 2018

3. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

4. Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer

5. Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering photodynamics for treatment, priming and imaging;Nature Reviews Bioengineering;2024-06-19

2. Overcoming the effects of fluid shear stress in ovarian cancer cell lines: Doxorubicin alone or photodynamic priming to target platinum resistance;Photochemistry and Photobiology;2024-06-07

3. Anti-tumor immune potentiation targets-engineered nanobiotechnologies: Design principles and applications;Progress in Materials Science;2024-04

4. Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids;Cell & Bioscience;2024-02-06